Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Incara Pharmaceuticals Closes on $10+ Million Financing

By Pharmaceutical Processing | April 20, 2004

RESEARCH TRIANGLE PARK, NC (April 19, 2004) – Incara Pharmaceuticals Corp. announced that it has closed a private placement raising approximately $10.26 million from the sale of more than 41 million shares of its common stock.

Incara is in final preparation of an Investigational New Drug (IND) application to be filed with the FDA for treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Incara intends to use the net proceeds from the financing to support the IND and clinical trials forAEOL 10150.

The company issued to all purchasers five-year warrants to purchase an aggregate number of shares of common stock equal to 40 percent of the total number of shares of common stock sold, at an exercise price of 40 cents per share, the company said.

Investors included Biotechnology Value Fund, Perceptive Life Sciences and Great Point Partners, according to Incara. SCO Securities LLC acted as exclusive placement agent for the transaction.

In connection with the financing, Goodnow Capital, LLC, an investment entity controlled by the Xmark Funds, advanced the remaining $2.5 million of its $5 million convertible debenture and converted the entire debenture into common stock. In addition, as a result of the financing, the warrant toacquire 12.5 million shares previously issued to Goodnow Capital expiredunexercised, according to Incara.

If the Phase 1 clinical trial results are satisfactory, Incara’s clinical plan calls for initiating a Phase 2/3 clinical trial of AEOL 10150 for treatment of ALS as early as the first half of 2005, the company said.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE